Saturday, 26 January 2013

Resistance To Anti-HER2 Therapy In Breast Cancer Patients May Be Delayed By Treatment Targeting PI3K

Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens. The data, published in Cancer Research, a journal of the American Association for Cancer Research, indicated that failure of the anti-HER2 antibody trastuzumab to block HER2 from activating the phosphatidylinositol-3 kinase (PI3K) signaling pathway can lead to resistance to treatment... via Health News from Medical News Today Read More Here..


Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/01/resistance-to-anti-her2-therapy-in.html

No comments:

Post a Comment